KaloBios Pharmaceuticals (KBIO) is a small-cap company focused on developing patient-targeted, first-in-class monoclonal antibodies using its proprietary Humaneered technology platform, with the intent to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, the company's primary clinical focus is treating infectious and respiratory diseases and cancer. KaloBios has two antibodies in Phase II clinical testing for the treatment of severe/persistent asthma and cystic fibrosis (CF) and prevention of ventilation-associated pneumonia (VAP). It also has a third antibody in Phase I clinical testing for hematological malignancies.
The Company's Pipeline:
1. Humaneered technology - The Humaneered technology forms the basis of the company's drug discovery and development. The technology first uses conventional methods to identify...
Only subscribers can access this article, which is part of the PRO research library covering 3,617 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: